Corcept Therapeutics, Inc. (CORT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1152732,
    "name": "Corcept Therapeutics, Inc.",
    "stock_name": "Corcept Therapeutics, Inc.",
    "full_name": "Corcept Therapeutics, Inc.",
    "name_url": "stocks-analysis/corcept-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "84.66",
    "chg": 3.9,
    "chgp": "4.83%",
    "dir": 1,
    "prev_price": "80.76",
    "mcapval": "7,922.40",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US2183521028",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.98 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/corcept-therapeutics-inc-1152732-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Corcept Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/corcept-therapeutics-technical-trend-changes-from-bullish-to-mildly-bullish-amid-stock-price-decline-3619779",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CorceptTherapeu_technicaldot_3619779.png",
        "date": "2025-10-14 15:46:32",
        "description": "Corcept Therapeutics, Inc. has recently revised its evaluation amid changing market conditions. The company's stock price is currently at $71.53, with a notable performance history, including a 286.65% increase over the past five and ten years, showcasing its resilience in the pharmaceutical sector."
      },
      {
        "title": "Is Corcept Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-corcept-therapeutics-inc-technically-bullish-or-bearish-3614545",
        "imagepath": "",
        "date": "2025-10-13 11:36:32",
        "description": "As of 10 October 2025, the technical trend for Corcept Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish. The Bollinger Bands and Dow Theory indicate a mildly bullish stance on both weekly and monthly time frames. The daily moving averages also suggest a mildly bullish trend. \n\nDespite a recent 1-week return of -16.10%, the stock has performed well over longer periods, with a year-to-date return of 46.78% compared to the S&P 500's 11.41%, and a 1-year return of 63.45% against the S&P 500's 13.36%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from MACD and the consistent mildly bullish indicators across multiple time frames...."
      },
      {
        "title": "Is Corcept Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-corcept-therapeutics-inc-technically-bullish-or-bearish-3612877",
        "imagepath": "",
        "date": "2025-10-12 11:24:52",
        "description": "As of 10 October 2025, the technical trend for Corcept Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands and Dow Theory both show mildly bullish trends on both weekly and monthly charts. The daily moving averages also reflect a mildly bullish stance. \n\nIn terms of performance, Corcept has outperformed the S&P 500 significantly over the longer term, with a 1-year return of 63.45% compared to the S&P 500's 13.36%, and a 5-year return of 303.05% versus the S&P 500's 88.45%. However, the stock has recently experienced a sharp decline of 16.10% over the past week, contrasting with the S&P 500's decline of only 2.43%. Overall, the current stance is mildly bullish, supported by several indicators, despite recent volatility...."
      },
      {
        "title": "Is Corcept Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-corcept-therapeutics-inc-technically-bullish-or-bearish-3546263",
        "imagepath": "",
        "date": "2025-09-20 19:28:09",
        "description": "As of 1 July 2025, the technical trend for Corcept Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish while the monthly MACD is bullish, indicating mixed signals. The weekly RSI is bearish, but the monthly RSI shows no signal. Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages are bullish, supporting a positive short-term outlook. Dow Theory and OBV both indicate a mildly bullish stance on weekly and monthly bases. \n\nCorcept has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 58.36% compared to the S&P's 12.22%, and a one-year return of 88.79% versus 17.14%. Overall, the current technical stance is mildly bullish, driven by strong performance in moving averages and Bollinger Bands, despite some bearish indicators in the MACD and RSI on the weekly timeframe...."
      },
      {
        "title": "Is Corcept Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-corcept-therapeutics-inc-overvalued-or-undervalued-3542864",
        "imagepath": "",
        "date": "2025-09-20 18:04:08",
        "description": "As of 4 August 2025, the valuation grade for Corcept Therapeutics, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is overvalued based on its high valuation ratios, including a P/E ratio of 59, an EV to EBITDA of 66.34, and a PEG ratio of 5.37. In comparison, peers such as ACADIA Pharmaceuticals, Inc. have a P/E of 19.28 and an EV to EBITDA of 33.99, highlighting the premium at which Corcept is trading.\n\nAdditionally, Corcept's recent stock performance has outpaced the S&P 500, with a year-to-date return of 58.36% compared to the index's 12.22%, and a one-year return of 88.79% versus 17.14%. This strong performance may reflect investor enthusiasm, but the elevated valuation ratios suggest that the stock may not be justified at its current price...."
      }
    ],
    "total": 10,
    "sid": "1152732",
    "stock_news_url": "https://www.marketsmojo.com/news/corcept-therapeutics-inc-1152732"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Corcept Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-14 15:46:32

Corcept Therapeutics, Inc. has recently revised its evaluation amid changing market conditions. The company's stock price is currently at $71.53, with a notable performance history, including a 286.65% increase over the past five and ten years, showcasing its resilience in the pharmaceutical sector.

Is Corcept Therapeutics, Inc. technically bullish or bearish?

2025-10-13 11:36:32

As of 10 October 2025, the technical trend for Corcept Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish. The Bollinger Bands and Dow Theory indicate a mildly bullish stance on both weekly and monthly time frames. The daily moving averages also suggest a mildly bullish trend. Despite a recent 1-week return of -16.10%, the stock has performed well over longer periods, with a year-to-date return of 46.78% compared to the S&P 500's 11.41%, and a 1-year return of 63.45% against the S&P 500's 13.36%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from MACD and the consistent mildly bullish indicators across multiple time frames....

Is Corcept Therapeutics, Inc. technically bullish or bearish?

2025-10-12 11:24:52

As of 10 October 2025, the technical trend for Corcept Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands and Dow Theory both show mildly bullish trends on both weekly and monthly charts. The daily moving averages also reflect a mildly bullish stance. In terms of performance, Corcept has outperformed the S&P 500 significantly over the longer term, with a 1-year return of 63.45% compared to the S&P 500's 13.36%, and a 5-year return of 303.05% versus the S&P 500's 88.45%. However, the stock has recently experienced a sharp decline of 16.10% over the past week, contrasting with the S&P 500's decline of only 2.43%. Overall, the current stance is mildly bullish, supported by several indicators, despite recent volatility....

Is Corcept Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:28:09

As of 1 July 2025, the technical trend for Corcept Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish while the monthly MACD is bullish, indicating mixed signals. The weekly RSI is bearish, but the monthly RSI shows no signal. Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages are bullish, supporting a positive short-term outlook. Dow Theory and OBV both indicate a mildly bullish stance on weekly and monthly bases. Corcept has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 58.36% compared to the S&P's 12.22%, and a one-year return of 88.79% versus 17.14%. Overall, the current technical stance is mildly bullish, driven by strong performance in moving averages and Bollinger Bands, despite some bearish indicators in the MACD and RSI on the weekly timeframe....

Is Corcept Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:04:08

As of 4 August 2025, the valuation grade for Corcept Therapeutics, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is overvalued based on its high valuation ratios, including a P/E ratio of 59, an EV to EBITDA of 66.34, and a PEG ratio of 5.37. In comparison, peers such as ACADIA Pharmaceuticals, Inc. have a P/E of 19.28 and an EV to EBITDA of 33.99, highlighting the premium at which Corcept is trading. Additionally, Corcept's recent stock performance has outpaced the S&P 500, with a year-to-date return of 58.36% compared to the index's 12.22%, and a one-year return of 88.79% versus 17.14%. This strong performance may reflect investor enthusiasm, but the elevated valuation ratios suggest that the stock may not be justified at its current price....

View All News